Andrew MD - Akero Therapeutics CEO President
| AKRO Stock | USD 22.99 0.03 0.13% |
CEO
Andrew MD is CEO President of Akero Therapeutics
| Age | 57 |
| Address | 601 Gateway Boulevard, South San Francisco, CA, United States, 94080 |
| Phone | 650 487 6488 |
| Web | https://akerotx.com |
Akero Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2023) % which means that it has lost $0.2023 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3111) %, meaning that it created substantial loss on money invested by shareholders. Akero Therapeutics' management efficiency ratios could be used to measure how well Akero Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 11th of June 2024, Return On Tangible Assets is likely to drop to -0.27. In addition to that, Return On Capital Employed is likely to drop to -0.32. At this time, Akero Therapeutics' Total Assets are very stable compared to the past year. As of the 11th of June 2024, Net Tangible Assets is likely to grow to about 394.3 M, though Non Currrent Assets Other are likely to grow to (0.95).Similar Executives
| Found 7 records | CEO Age | ||
| Dinesh Patel | Protagonist Therapeutics | 67 | |
| Brian Lian | Viking Therapeutics | 58 | |
| William MD | Passage Bio | 50 | |
| Amy MBA | Terns Pharmaceuticals | 53 | |
| Mark Goldsmith | Revolution Medicines | 62 | |
| William Sibold | Madrigal Pharmaceuticals | 58 | |
| Sarah Boyce | Avidity Biosciences | 52 | |
Management Performance
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.2 |
Akero Therapeutics Leadership Team
Elected by the shareholders, the Akero Therapeutics' board of directors comprises two types of representatives: Akero Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Akero. The board's role is to monitor Akero Therapeutics' management team and ensure that shareholders' interests are well served. Akero Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Akero Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Timothy Rolph, CoFounder Officer | ||
| Patrick Lamy, Senior Strategy | ||
| Andrew MD, CEO President | ||
| Catriona Yale, Executive Officer | ||
| William JD, CFO, VP | ||
| Dr JD, Executive CoFounder | ||
| John Schembri, VP Controller |
Akero Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Akero Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.2 | ||||
| Current Valuation | 724.01 M | ||||
| Shares Outstanding | 69.15 M | ||||
| Shares Owned By Insiders | 5.43 % | ||||
| Shares Owned By Institutions | 94.57 % | ||||
| Number Of Shares Shorted | 8.33 M | ||||
| Price To Earning | (7.43) X | ||||
| Price To Book | 2.86 X | ||||
| EBITDA | (172.84 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Information and Resources on Investing in Akero Stock
When determining whether Akero Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Akero Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Akero Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Akero Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akero Therapeutics. If investors know Akero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.24) | Return On Assets (0.20) | Return On Equity (0.31) |
The market value of Akero Therapeutics is measured differently than its book value, which is the value of Akero that is recorded on the company's balance sheet. Investors also form their own opinion of Akero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akero Therapeutics' market value can be influenced by many factors that don't directly affect Akero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.